Lesson
Build the Immune Keratinocyte Axis
Psoriasis is not simply rapid skin growth. Genetic susceptibility, innate immune activation, IL-23 dependent T cell signaling, IL-17 and TNF, and keratinocyte feedback create a self-reinforcing inflammatory circuit.
- Dendritic cell
- IL-23
- Th17
- IL-17
- TNF
- Keratinocyte
Dendritic and tissue signals establish an IL-23 rich inflammatory environment.
IL-17 and TNF activate keratinocytes and recruit additional immune cells.
Accelerated turnover, incomplete maturation, vessels, and inflammation create scale and erythema.
Start with immune activation
Dendritic cells and other innate signals promote IL-23 dependent survival and activation of type 17 immune responses. Genetic susceptibility, infection, trauma, smoking, obesity, and medicine exposure can influence expression without explaining every case.
Follow the cytokine circuit
IL-17A, IL-17F, TNF, and related mediators activate keratinocytes. Keratinocytes then release chemokines, antimicrobial peptides, and inflammatory signals that recruit more immune cells and sustain the lesion.
Explain the plaque
Accelerated epidermal turnover, incomplete maturation, vascular dilation, and inflammatory cell accumulation produce sharply demarcated erythematous plaques with scale. Pinpoint bleeding after scale removal is a classic finding, not a test that must be provoked.
Use the Koebner phenomenon
New lesions can appear at sites of trauma. Scratching, friction, burns, tattoos, or procedures can reproduce disease in susceptible skin, which makes skin protection part of management.
Map treatment to biology
Corticosteroids reduce broad inflammation, vitamin D analogs influence keratinocyte differentiation, PDE4 and TYK2 inhibitors reduce intracellular signaling, and biologics selectively block TNF, IL-12/23, IL-17, or IL-23 pathways.
Quick check
Checking for saved practice…
Lesson
Recognize Phenotype, Site, and Urgency
The word psoriasis does not define one presentation. Morphology, distribution, symptoms, systemic illness, and recent medicine changes separate routine plaque care from urgent erythrodermic or pustular disease.
- Plaque
- Inverse
- Guttate
- Nail
- Erythrodermic
- Generalized pustular psoriasis
Scalp, folds, nails, palms, soles, face, and genitals can change treatment and burden.
An abrupt small lesion eruption can follow infection without proving active infection remains.
Generalized pustules, erythroderma, fever, pain, or organ dysfunction require urgent care.
Recognize plaque disease
Stable plaque psoriasis usually produces well demarcated erythematous plaques with scale on extensor surfaces, scalp, trunk, or other sites. Pruritus, pain, fissuring, and sleep disruption can be substantial even when extent is limited.
Assess inflammation across skin tones
Inflamed skin may appear red, purple, darker than surrounding skin, or have little obvious color change depending on skin tone. Assess scale, thickness, warmth, pain and systemic symptoms rather than requiring bright redness to recognize serious disease.
Identify special sites
Inverse disease affects folds with less visible scale. Genital, facial, scalp, palmoplantar, and nail disease can create disproportionate functional and psychosocial burden. Nail pitting, onycholysis, and subungual hyperkeratosis also increase suspicion for psoriatic arthritis.
Recognize guttate disease
An abrupt eruption of many small lesions often follows streptococcal infection, especially in younger patients. Confirm the pattern and assess the trigger rather than prescribing antibiotics for psoriasis without evidence of active infection.
Escalate erythroderma
Near generalized erythema and scale can impair temperature control and fluid balance and can accompany infection, high output cardiac stress, or medication withdrawal. Systemic instability requires emergency evaluation; extensive erythroderma warrants urgent specialist assessment.
Escalate pustular disease
Generalized sterile pustules with erythema, pain, fever, malaise, leukocytosis, or organ dysfunction suggest generalized pustular psoriasis. This is distinct from plaque psoriasis and can be life threatening.
Quick check
Checking for saved practice…
Lesson
Measure Disease Beyond Surface Area
Body surface area is useful but incomplete. Severity also lives in lesion intensity, symptoms, special sites, function, quality of life, joint disease, comorbidity, and failure of appropriate treatment.
- BSA
- PGA
- PASI
- DLQI
- Special sites
- Psoriatic arthritis
Extent and global assessment establish a reproducible objective baseline.
Pain, itch, sleep, function, intimacy, work, and treatment effort reveal hidden severity.
Psoriatic arthritis, cardiometabolic risk, bowel disease, mood, and uveitis change care.
Quantify extent and intensity
The palmar surface of the patient's hand, including fingers, approximates one percent body surface area. Physician Global Assessment describes overall morphology. PASI is common in trials, while BSA and global assessment are often more practical in routine care.
Measure patient burden
Pruritus, pain, sleep, clothing, intimacy, work, sport, treatment effort, and confidence reveal burden that extent misses. DLQI, Psoriasis Symptom Inventory, and similar tools can make that burden visible.
Protect special sites
Disease of the face, genitals, hands, feet, scalp, or nails may justify advanced therapy despite limited BSA because it can impair identity, mobility, work, sleep, or relationships.
Screen for psoriatic arthritis
Ask about prolonged morning stiffness, swollen joints, dactylitis, heel or tendon pain, inflammatory back symptoms, and functional decline. Suspected inflammatory joint disease warrants rheumatology evaluation before irreversible damage accumulates.
Screen systemic comorbidity
Review cardiovascular risk, obesity, diabetes, hypertension, dyslipidemia, smoking, alcohol, depression, suicidality, inflammatory bowel disease, uveitis, liver disease, and treatment specific infection risk.
Quick check
Checking for saved practice…
Lesson
Engineer a Topical Regimen That Can Work
Topical success depends on active ingredient, potency, vehicle, site, duration, quantity, technique, and a plan the patient can sustain. A prescription without those choices is incomplete.
- Corticosteroid potency
- Vitamin D analog
- Tazarotene
- Calcineurin inhibitor
- Keratolytic
- Vehicle
Ointment, cream, solution, and foam solve different site and adherence problems.
Corticosteroid potency and duration must fit plaque thickness and skin vulnerability.
Check product limits: tazarotene pregnancy restrictions, calcium risk with vitamin D analogs, and off-label calcineurin use.
Match vehicle to site
Ointments are occlusive and useful for thick dry plaques, creams are versatile, solutions and foams can improve scalp delivery, and patient preference can determine whether any product is actually used.
Use corticosteroid potency deliberately
Potent agents can control thick plaques, while face, folds, and genital skin require lower exposure and steroid sparing strategies. Prolonged or excessive use can cause atrophy, striae, telangiectasia, and systemic absorption. If control worsens, reassess application, adherence and the diagnosis rather than automatically escalating potency.
Combine complementary mechanisms
Vitamin D analogs such as calcipotriene influence proliferation and differentiation and are often paired with corticosteroids. Combination products can improve efficacy and simplify use while retaining dose and site limits.
Use steroid sparing options
Tazarotene can reduce plaque thickness but irritates and is avoided in pregnancy. Topical calcineurin inhibitors are used off label on sensitive areas because they avoid steroid atrophy, but can burn and carry labeling precautions.
Apply tazarotene pregnancy safeguards
Topical tazarotene is contraindicated during pregnancy. For patients who can become pregnant, obtain a negative test within two weeks before starting and use effective contraception during treatment; the Tazorac cream label directs initiation during a menstrual period. Stop if pregnancy occurs. Topical administration does not eliminate fetal risk.
Teach the actual tazarotene formulation
For Tazorac cream plaque psoriasis, start with 0.05% and increase to 0.1% only when tolerated and indicated. Apply a thin layer to lesions on dry skin each evening; use emollient at least an hour beforehand. Protect against sun exposure and avoid eczematous skin. Significant irritation may require interruption or a lower strength. Psoriasis evidence under age 18 is not established for this cream; acne age labeling does not establish pediatric psoriasis use.
Check calcium and site with calcipotriene
The reviewed 0.005% cream is applied twice daily and should not be used on the face, with hypercalcemia, or with vitamin D toxicity. Stop if serum calcium rises above normal until it normalizes. Product hypersensitivity is a contraindication. Pediatric safety and effectiveness are not established for this cream. Other vehicles and steroid combinations have their own schedules, age boundaries and site limits; do not transfer these directions automatically.
Prescribe the combination product precisely
Duobrii combines halobetasol 0.01% with tazarotene 0.045% for adult plaque psoriasis. Apply once daily on dry affected skin, limit use to 50 g weekly, and stop when controlled. Avoid face, groin, axillae and unprescribed occlusion. It retains tazarotene pregnancy testing, contraception and pregnancy contraindication plus corticosteroid atrophy and adrenal-suppression risks.
Distinguish calcipotriene-steroid foam instructions
Enstilar is labeled from age 12: shake, apply once daily for up to four weeks, stop when controlled, and do not exceed 60 g per four days. Avoid face, groin, axillae, atrophic skin and unprescribed occlusion. Avoid flames and smoking during and immediately after application. Stop for elevated serum or urinary calcium until normalized. Review cumulative steroid exposure, adrenal suppression and visual symptoms. Trials of longer maintenance do not change the regimen stated in the US dosage section.
Keep anthralin distinct from salicylic acid
Anthralin is a separate antipsoriatic ingredient, not another name for salicylic acid or an assurance that a product contains it. Vehicle composition and contact time vary. Verify the actual preparation and wash-off instructions, protect uninvolved skin and avoid eyes and mucosa; irritation and staining limit use.
Support the skin barrier
Use a fragrance-free moisturizer regularly and after washing; choose a cream or ointment the patient can sustain. Gentle scale softening can improve comfort and topical delivery. Avoid forceful scraping, which can injure skin and provoke lesions. Moisturizers complement treatment across disease severities; they do not replace systemic assessment when disease is unstable.
Counsel coal tar beyond odor and staining
Coal tar can increase ultraviolet sensitivity and cause irritation or acne-like eruptions. Avoid unsupervised tanning or extra sun exposure; any combined phototherapy needs a prescribed protocol. Do not wrap treated skin or apply to genital or rectal areas unless specifically directed. For scalp shampoos, deliver the product to the scalp rather than only the hair. Pregnancy and breastfeeding require discussion of alternatives because safety information is limited.
Use older adjuncts selectively
Salicylic acid can remove scale but increases absorption of other topicals and can cause toxicity over large areas. Coal tar and anthralin can help selected patients but odor, staining, irritation, and complex technique limit use.
Quick check
Checking for saved practice…
Lesson
Use Modern Nonsteroidal Topicals Precisely
Tapinarof and roflumilast expand nonsteroidal treatment, especially when long term steroid burden, special sites, or vehicle preference matters. Their formulations and age boundaries are not interchangeable.
- Tapinarof
- Aryl hydrocarbon receptor
- Roflumilast
- PDE4
- Cream
- Foam
A thin layer once daily treats adult plaque psoriasis without topical corticosteroid exposure.
Roflumilast 0.3 percent treats plaques including folds. Check hepatic contraindications; eczema strengths differ.
From age 12, foam improves hair bearing delivery with essential flammability counseling.
Use tapinarof for adult plaque psoriasis
Tapinarof cream 1 percent is an aryl hydrocarbon receptor agonist applied as a thin layer once daily to affected areas in adults. Wash hands afterward unless the hands are treated.
Counsel tapinarof adverse effects
Folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza were among reactions reported more often than vehicle in plaque psoriasis trials. Reassess irritation rather than layering more product.
Use roflumilast cream
Roflumilast cream 0.3 percent is a topical PDE4 inhibitor for plaque psoriasis in patients two years and older under current labeling. Apply once daily, including intertriginous areas when affected.
Use roflumilast foam
Roflumilast foam 0.3 percent treats scalp and body plaque psoriasis in patients 12 years and older. Shake, apply once daily to dry affected skin or scalp, rub in, wash hands, and avoid flame or smoking during and immediately after use.
Do not transfer an eczema indication
For plaque psoriasis, roflumilast cream uses the 0.3 percent strength. The 0.15 and 0.05 percent creams have separate atopic dermatitis indications. Likewise, tapinarof's atopic dermatitis indication from age two does not change its adult-only plaque psoriasis indication. Check diagnosis, concentration and age together.
Review roflumilast interactions
Systemic CYP3A4 inhibitors, combined CYP3A4/CYP1A2 inhibitors, and gestodene/ethinyl estradiol contraceptives may raise roflumilast exposure. Weigh added adverse-effect risk against benefit with the prescriber rather than assuming a topical product cannot interact. These warnings are not a blanket instruction to stop contraception.
Respect systemic boundaries
Both roflumilast formulations are contraindicated in moderate to severe hepatic impairment. Diarrhea, headache, insomnia, nausea, and local reactions can occur, and interaction review matters because topical exposure is not zero.
Quick check
Checking for saved practice…
Lesson
Use Light as a Measured Treatment
Phototherapy is controlled treatment, not a recommendation to tan. Wavelength, dose, schedule, photosensitizing medicines, skin type, cumulative exposure, and access determine whether it is appropriate.
- Narrowband UVB
- Targeted UVB
- Excimer
- PUVA
- Photosensitizer
- Cumulative exposure
Measured UVB can treat plaque or guttate disease without psoralen photosensitization.
Excimer and targeted systems reduce exposure of uninvolved skin.
Oral psoralen requires timed UVA-blocking eye protection, sun precautions, medication review and skin surveillance.
Prefer narrowband UVB for many patients
Narrowband UVB is a common office based option for widespread plaque or guttate psoriasis. It reduces inflammatory signaling and can be used without an oral photosensitizer.
Respond to erythema before the next session
The AAD narrowband-UVB pathway uses three sessions weekly and adjusts exposure by the degree and duration of redness. Redness persisting beyond 48 hours calls for withholding that day's treatment and returning to a previously tolerated dose under the phototherapy team's protocol. Do not automatically increase exposure after a burn or apply a broadband-UVB missed-session schedule to another modality.
Address folate during pregnancy planning
Narrowband UVB can be considered during pregnancy and breastfeeding. The 2022 BAD/BPG guideline advises considering folate measurement when trying to conceive and supplementation with prolonged whole-body courses, with particular attention during the first trimester. Coordinate the plan with dermatology and obstetric care; these recommendations do not make oral PUVA equivalent to narrowband UVB.
Target limited disease
Excimer laser and other targeted UVB systems concentrate treatment on localized plaques and reduce exposure of uninvolved skin. They still require controlled dosing and eye protection.
Understand PUVA
Psoralen plus UVA can be effective but adds systemic or topical photosensitization, eye protection requirements, drug interactions, nausea with oral psoralen, and greater cumulative carcinogenic concern.
Make oral PUVA precautions concrete
Methoxsalen formulation and UVA timing must match the specialist protocol: soft capsules and older hard capsules differ in exposure and photosensitization. Use treatment goggles during irradiation and prescribed UVA-blocking wraparound eyewear after ingestion; ordinary sunglasses are inadequate. The oral label requires protection for 24 hours after ingestion and after combined treatment, avoidance of sun exposure even through glass, and no sunbathing for 48 hours after treatment. Provide written timing instructions rather than relying on sunscreen alone.
Screen before psoralen exposure
Review photosensitivity disorders, psoralen reactions, melanoma history, invasive squamous-cell cancer and aphakia before oral methoxsalen. Arrange baseline and annual eye examinations and ongoing skin-cancer surveillance. Review photosensitizing medicines and cumulative UVA exposure. These oral-psoralen precautions should not be transferred wholesale to narrowband UVB or a different psoralen formulation.
Prevent treatment injury
Review photosensitizing medicines, prior skin cancer, burns, pigment response, and exposure history. Erythema timing guides dose adjustment, and blistering is toxicity rather than proof of efficacy.
Design for feasibility
Travel, work, copay, equipment access, home unit quality, and frequency often determine adherence. A theoretically effective plan that a patient cannot attend is not an effective plan.
Quick check
Checking for saved practice…
Lesson
Select Oral Systemic Therapy by Patient Constraint
Oral systemic drugs differ more than their route suggests. Speed, organ toxicity, reproductive risk, infection, interaction burden, renal function, and monitoring determine which option is usable.
- Methotrexate
- Cyclosporine
- Acitretin
- Apremilast
- Deucravacitinib
- TYK2
Methotrexate, cyclosporine, and acitretin require distinct organ and reproductive safeguards.
Immediate-release and XR doses differ. Severe renal impairment requires immediate-release adjustment; avoid XR.
Deucravacitinib requires infection, vaccine, liver, triglyceride and muscle-symptom review.
Distinguish historical off-label options
RxPrep lists hydroxyurea among systemic options. AAD discusses it as an off-label psoriasis treatment, not an FDA-approved psoriasis indication. It is not a routine substitute for established therapies; specialist selection requires its own toxicity and monitoring review.
Use methotrexate with weekly discipline
Methotrexate can treat skin and joint disease but requires strict weekly dosing, blood count, renal and hepatic assessment, interaction review, reproductive planning, and counseling about infection and pulmonary or hepatic toxicity.
Write an unambiguous methotrexate prescription
The reviewed oral label uses 10 to 25 mg once weekly for severe adult psoriasis, with gradual adjustment and a 30 mg weekly ceiling. Specify the weekly day, total milligrams and tablet count; do not import oncology schedules. Provide prescribed folic or folinic acid supplementation. For example, 15 mg using 2.5 mg tablets means six tablets on the weekly dosing day, not six days of treatment. Accidental daily dosing requires immediate toxicity evaluation and no further doses pending assessment.
Make methotrexate monitoring meaningful
Obtain baseline and follow-up blood counts, kidney function and liver tests. Normal transaminases do not exclude fibrosis in psoriasis; assess liver risk, including alcohol exposure. AAD guidance recommends noninvasive testing for hepatic fibrosis rather than relying on transaminases alone. Arrange baseline fibrosis assessment and specialist follow-up for abnormal findings; the monitoring plan must account for individual risk and treatment duration. AAD's systemic-treatment tables also include baseline tuberculosis and hepatitis B/C screening. For stable patients without abnormal results, those tables list blood counts and liver tests every three to six months; this is not a default waiting period after initiation, dose changes, new interacting medicines or suspected toxicity. Such changes require an individualized earlier check. New mouth ulcers, bleeding, fever, dyspnea or persistent cough warrant prompt assessment for toxicity or infection. Pregnancy is contraindicated for psoriasis treatment; verify pregnancy status and provide reproductive counseling before starting.
Check methotrexate interactions before each new medicine
Antifolates, sulfonamide or penicillin antibiotics, NSAIDs, proton pump inhibitors and nephrotoxic or hepatotoxic drugs can increase toxicity risk. Review necessity, renal function and monitoring rather than treating every combination as an absolute contraindication. Avoid nitrous oxide anesthesia and tell dental or anesthesia teams about methotrexate. Renal impairment or substantial ascites/pleural effusions can delay elimination.
Separate label counseling from overdose rescue
The reviewed US label specifies contraception during treatment and for six months afterward for patients who can become pregnant, and three months afterward for males with partners who can become pregnant. It advises no breastfeeding during treatment and for one week afterward. Reproductive specialists may individualize decisions using current guidance. Routine folate supplementation is not an overdose-management plan: accidental excess dosing needs urgent evaluation, even without symptoms, and clinician-directed leucovorin or levoleucovorin rescue when indicated.
Explain reproductive guideline differences
For rheumatic disease, including relevant PsA care, the EULAR 2024 update published in 2025 advises stopping maternal methotrexate one to three months before conception, while permitting paternal continuation at doses up to 25 mg weekly. It allows consideration of methotrexate up to 25 mg weekly during breastfeeding only when no compatible alternative can be used, on limited evidence. These differ from the US label intervals above and from ACR 2020's recommendation against breastfeeding use. Document the specialist's individualized plan and its source; do not generalize paternal compatibility to maternal pregnancy or to higher doses.
Use cyclosporine for rapid control
Cyclosporine can act quickly in severe, recalcitrant, pustular, or erythrodermic disease but nephrotoxicity, hypertension, interactions, malignancy risk, and duration limits make it a monitored bridge rather than a casual long term choice.
Respect cyclosporine eligibility and interactions
The US Neoral plaque-psoriasis indication is for nonimmunocompromised adults with severe recalcitrant disease after systemic-treatment failure, contraindication or intolerance. Abnormal renal function, uncontrolled hypertension and malignancy exclude psoriasis use under the label. Do not combine with methotrexate, other immunosuppressants, PUVA, UVB, coal tar or radiation therapy. The rheumatoid-arthritis methotrexate combination indication does not authorize that psoriasis combination. Review CYP3A4/P-glycoprotein interactions, nephrotoxic medicines and potassium-raising drugs; avoid grapefruit and keep meal timing consistent.
Specify modified cyclosporine
Neoral starts at 2.5 mg/kg/day split into two doses for psoriasis, not 2.5 mg/kg per dose. After four weeks, inadequate response may justify 0.5 mg/kg/day increases every two weeks, up to 4 mg/kg/day. Stop for unsatisfactory response after six weeks at the maximum tolerated dose. Continuous treatment beyond one year is not recommended. Modified cyclosporine and Sandimmune are not bioequivalent; formulation changes require supervision.
Use psoriasis-specific cyclosporine monitoring
Establish blood pressure and creatinine on two occasions. Monitor these and BUN every two weeks for three months, then monthly if stable, alongside CBC, potassium, magnesium, uric acid and lipids. A creatinine increase of at least 25% warrants repeat testing within two weeks; persistence requires a 25% to 50% dose reduction. An increase of at least 50% warrants dose reduction immediately. Stop if creatinine cannot return within 25% of baseline after two dose modifications. Do not combine psoriasis cyclosporine with PUVA, UVB or other immunosuppressants.
Use acitretin within absolute reproductive safeguards
Acitretin treats severe psoriasis and can help pustular disease without broad immunosuppression. It is highly teratogenic, requires pregnancy avoidance for at least three years after discontinuation, and requires lipid, hepatic, mucocutaneous, skeletal, and alcohol counseling.
Dose and screen acitretin
Acitretin comes as capsules. The US label starts 25 to 50 mg once daily with the main meal, individualized to response. Contraindications include severe hepatic or renal impairment, chronically abnormal elevated lipids, retinoid hypersensitivity, and concurrent methotrexate or tetracyclines. Avoid supplemental vitamin A and other oral retinoids.
Make acitretin monitoring explicit
Obtain baseline fasting lipids and liver tests, repeating every one to two weeks until stable. Pregnancy testing includes two negative tests before initiation, monthly tests during treatment, and tests every three months for at least three years afterward. Follow the label's test timing, contraception exceptions and consent process. When contraception is required, use two methods starting one month before therapy; a microdosed progestin minipill is unsuitable. Dispense no more than a month's supply with the Medication Guide.
Separate acitretin safety timelines
Patients who can become pregnant must avoid ingested ethanol in drinks, food and medicines during treatment and for two months afterward because it can promote formation of long-lasting etretinate. This does not shorten pregnancy prevention, which continues for at least three years after stopping. All patients, including men, must avoid blood donation during treatment and for at least three years afterward. Follow the label's signed consent, pregnancy testing and contraception requirements before dispensing; generic alcohol counseling is insufficient.
Use apremilast with titration and renal adjustment
Apremilast inhibits PDE4 and is titrated to reduce gastrointestinal effects. Monitor weight and mood. Strong CYP inducers can reduce exposure. In adults with creatinine clearance below 30 mL/min, use only the morning immediate-release titration doses, then 30 mg once daily. Otezla XR is not recommended in severe renal impairment.
Distinguish apremilast release formulations
After the five-day immediate-release titration, adult maintenance is Otezla 30 mg twice daily or Otezla XR 75 mg once daily starting on day six. These are labeled alternatives, not a milligram-for-milligram substitution. An established patient may switch between those regimens the next day after the last dose. Pediatric plaque-psoriasis eligibility begins at age six and 20 kg; maintenance is immediate-release 20 mg twice daily below 50 kg. At 50 kg or more, either adult maintenance regimen is labeled after appropriate titration. Check renal function before selecting any regimen.
Act on apremilast safety signals
Take either formulation intact, with or without a meal; do not divide, chew, or crush tablets. Severe vomiting or diarrhea warrants prompt assessment for dehydration and possible dose reduction or interruption, especially in older adults or patients taking volume-depleting medicines. New depression or suicidal thoughts requires prompt clinical reassessment; prior depression calls for individualized risk-benefit review rather than an automatic contraindication. Evaluate significant or unexplained weight loss, and track height and weight in children. Serious allergy requires discontinuation and appropriate treatment.
Adjust pediatric apremilast for severe renal impairment
For eligible children with severe renal impairment, use the weight-appropriate morning-only immediate-release titration. Maintenance is 20 mg once daily at 20 to less than 50 kg, or 30 mg once daily at 50 kg or more. Extended-release apremilast is not recommended in this setting. Confirm pediatric renal assessment with the treating team before applying a dose adjustment.
Use deucravacitinib as a selective TYK2 inhibitor
Deucravacitinib 6 mg daily is labeled for adult systemic-treatment or phototherapy candidates with moderate to severe plaque psoriasis and for active adult PsA. Swallow tablets intact; meals are optional. Combining with potent immunosuppressants is not recommended. Assess TB and vaccines before treatment; begin latent-TB treatment first and avoid active TB, active or serious infection, and live vaccines. Review hepatitis risk; active hepatitis B or C is not recommended. Renal impairment, including dialysis, does not require adjustment; Child-Pugh C use is not recommended.
Make TYK2 monitoring actionable
Check triglycerides periodically and liver enzymes when liver disease is known or suspected. Unexplained muscle symptoms need assessment; discontinue for suspected myopathy or markedly elevated CPK. Consider malignancy history individually. Selectivity does not prove freedom from JAK-related harms: the label describes uncertain applicability of JAK safety signals, including cardiovascular, thrombosis and malignancy concerns. Patients with diabetes should report hypoglycemia symptoms. Interrupt for serious infection or suspected drug-induced liver injury; reassess before restarting.
Quick check
Checking for saved practice…
Lesson
Choose a Biologic Pathway, Not Just a Brand
Biologic selection begins with the target and the patient. Skin efficacy, joint disease, inflammatory bowel disease, infection, liver disease, weight, injection schedule, pregnancy planning, and access can point in different directions.
- TNF
- IL-12/23
- IL-17A
- IL-17 receptor
- IL-17A and F
- IL-23 p19
Match exact indications. TNF-specific heart-failure and demyelination concerns do not automatically apply to p40 blockade.
Review bowel and infection risk. Brodalumab has a boxed warning and REMS; bimekizumab also needs mood and liver review.
Long intervals and strong skin efficacy can be useful when the comorbidity profile fits.
Map the major families
TNF inhibitors include adalimumab, certolizumab, etanercept, and infliximab. Ustekinumab blocks IL-12/23 p40. IL-17 pathway agents include secukinumab, ixekizumab, brodalumab, and bimekizumab. Guselkumab, risankizumab, and tildrakizumab block IL-23 p19.
Use comorbidity as a selector
Psoriatic arthritis may favor agents with joint indications. Active inflammatory bowel disease can steer away from IL-17 pathway therapy. Heart failure, demyelinating disease, recurrent infection, hepatitis, and pregnancy planning can alter the balance for TNF and other pathways.
Screen before immune modulation
Evaluate active and latent infection, TB, hepatitis risk when relevant, vaccines, malignancy history, inflammatory bowel disease, mood history, and baseline laboratory needs according to the exact product. Avoid live vaccines during many biologic regimens.
Distinguish adalimumab precautions from absolute contraindications
For adult plaque psoriasis, adalimumab starts at 80 mg subcutaneously, followed one week later by 40 mg every other week. Heart failure and demyelinating disorders require caution and assessment; they are not listed as universal absolute contraindications in the Humira label. Monitor hepatitis-B carriers during and for several months after therapy; reactivation requires stopping treatment and antiviral care. Consider discontinuation for new demyelination. Do not substitute a hidradenitis or bowel-disease loading regimen.
Match etanercept to age and phase
Adult plaque psoriasis uses 50 mg subcutaneously twice weekly for three months, then 50 mg once weekly. From age four, pediatric psoriasis uses 0.8 mg/kg once weekly, capped at 50 mg; the adult induction schedule does not apply. Use an appropriate vial presentation for doses other than 25 or 50 mg. Current Enbrel devices are not made with natural rubber latex; do not carry forward an older device warning without checking the product.
Keep certolizumab psoriasis dosing distinct
The standard adult plaque-psoriasis dose is 400 mg subcutaneously every other week, as two separate 200 mg injections. For selected patients weighing 90 kg or less, 400 mg at weeks zero, two and four followed by 200 mg every other week can be considered. Do not substitute the every-four-week maintenance used for other indications. The prefilled-syringe cap contains a natural-rubber-latex derivative; check sensitivity. Combining with another biologic DMARD or TNF blocker is not recommended.
Use infliximab with infusion safeguards
Adult severe plaque psoriasis uses 5 mg/kg intravenously at weeks zero, two and six, then every eight weeks. Assess TB before and periodically during therapy and provide staff and medicines for infusion reactions; severe hypersensitivity requires stopping the infusion. Doses above 5 mg/kg are contraindicated in moderate or severe heart failure. Lower doses are not risk free: if used in heart failure, monitor closely and stop for new or worsening symptoms. Do not import the Crohn-disease escalation regimen into the psoriasis label.
Use ustekinumab's psoriasis regimen
Ustekinumab blocks IL-12/23 p40. Adult plaque psoriasis uses 45 mg subcutaneously at weeks zero and four, then every 12 weeks; use 90 mg when weight exceeds 100 kg. From age six, pediatric doses are 0.75 mg/kg below 60 kg, 45 mg at 60 to 100 kg, and 90 mg above 100 kg, on the same schedule. Bowel-disease induction is a separate regimen.
Recognize ustekinumab-specific safeguards
Evaluate new headache with confusion, seizures or visual disturbance urgently for PRES; discontinue if suspected. New cough or dyspnea requires evaluation for infection and noninfectious pneumonia; discontinue confirmed noninfectious pneumonia. Avoid live vaccines, with a specific BCG exclusion during treatment and for one year before and after. The Stelara prefilled-syringe needle cover contains natural rubber; latex-sensitive people should not handle it. Check the exact product and device rather than extending that warning to every biologic.
Know the important exceptions
Brodalumab blocks the IL-17 receptor and retains a boxed warning and restricted REMS for suicidal ideation and behavior, with Crohn disease contraindication. Bimekizumab blocks IL-17A and IL-17F and requires TB evaluation, liver testing, vaccination review, and attention to infections including candidiasis and to inflammatory bowel disease.
Specify secukinumab's psoriasis schedule
Adults receive 300 mg subcutaneously at weeks zero, one, two, three and four, then every four weeks; 150 mg may suffice for selected adults. Pediatric psoriasis treatment starts at age six: below 50 kg use 75 mg, and at 50 kg or more use 150 mg on the same schedule. Do not transfer intravenous arthritis regimens to plaque psoriasis. Serious infection requires interruption; active viral hepatitis is not recommended, and possible HBV reactivation needs specialist evaluation. Review IBD and device-specific latex risk: the Sensoready cap and 75 mg/150 mg prefilled-syringe caps contain natural rubber latex.
Separate adult and pediatric ixekizumab loading
Adult plaque psoriasis starts with 160 mg subcutaneously, then 80 mg every two weeks through week 12, then every four weeks. Pediatric psoriasis from age six uses loading/maintenance pairs of 40/20 mg below 25 kg, 80/40 mg at 25 to 50 kg, and 160/80 mg above 50 kg; maintenance is every four weeks without the adult every-two-week phase. Pediatric injections require a trained caregiver or healthcare professional. When smaller syringes are unavailable, preparation of 20 mg or 40 mg from an 80 mg prefilled syringe is a healthcare-professional procedure, not partial autoinjector dosing. Discontinue for new IBD and arrange treatment.
Apply brodalumab eligibility and follow-up
Brodalumab is an adult option after other systemic therapies have failed or lost effect. Inject 210 mg subcutaneously at weeks zero, one and two, then every two weeks. Consider stopping for inadequate response by weeks 12 to 16. Crohn disease is a contraindication; discontinue if it develops. Screen TB, treat latent TB before starting, and withhold for active TB. Serious infection warrants interruption until resolution.
Make the brodalumab REMS operational
Prescriber and pharmacy certification plus signed patient enrollment are required; dispense only to authorized patients. Explain the boxed warning and promptly evaluate new depression or suicidal thoughts, with appropriate mental-health referral and reconsideration of therapy. Causality has not been established, but this does not remove the required safety response. Previous depression calls for individualized risk-benefit assessment rather than being listed as an absolute contraindication.
Reassess a new eruption during IL-17 therapy
A new eczematous rash on brodalumab, secukinumab or ixekizumab may be an adverse reaction rather than uncontrolled psoriasis. Severe cases may require discontinuation; selected patients can continue with directed eczema treatment. Assess the eruption before escalating psoriasis therapy.
Match bimekizumab dose to the indication
Plaque psoriasis uses 320 mg subcutaneously at weeks zero, four, eight, 12 and 16, then every eight weeks. At 120 kg or more, consider every-four-week maintenance. PsA alone uses 160 mg every four weeks; coexisting moderate to severe plaque psoriasis uses the psoriasis regimen. Verify whether the device contains 160 or 320 mg before counting injections.
Monitor bimekizumab beyond candidiasis
Check transaminases, alkaline phosphatase and bilirubin before treatment and periodically. Avoid acute liver disease or cirrhosis. Interrupt suspected drug-induced liver injury; permanently stop causally associated combined transaminase and bilirubin elevations. Avoid active IBD and discontinue for new or worsening IBD symptoms. Clinically important infection requires withholding therapy. Assess TB and vaccines before treatment.
Include bimekizumab mood counseling
Bimekizumab also carries a suicidality precaution, without brodalumab's boxed warning or REMS. Review severe depression and suicidality history, explain prompt reporting of mood changes, and arrange appropriate mental-health assessment while reconsidering treatment. The observed signal does not establish causation.
Distinguish p19 psoriasis schedules
Guselkumab uses 100 mg subcutaneously at weeks zero and four, then every eight weeks. Its pediatric psoriasis indication requires both age six or older and weight at least 40 kg; a trained caregiver or healthcare professional administers pediatric doses. Risankizumab uses 150 mg at weeks zero and four, then every 12 weeks in adults. From age six, its pediatric dose is 55 mg below 40 kg and 150 mg at 40 kg or more. Ages six to under ten require adult administration; from ten, adult administration or supervision is recommended.
Plan tildrakizumab administration
Tildrakizumab is labeled for adult plaque psoriasis: 100 mg subcutaneously at weeks zero and four, then every 12 weeks. A healthcare provider administers the full 1 mL prefilled syringe. It is not a patient self-injection product, and the psoriasis indication does not establish a joint or bowel indication. Evaluate TB, start latent-TB treatment before use, and withhold in active TB. Clinically important infection requires assessment and consideration of interruption; serious hypersensitivity requires immediate discontinuation and treatment.
Keep p19 liver monitoring indication specific
For guselkumab psoriasis or PsA, obtain liver enzymes and bilirubin at baseline and periodically when clinically indicated. Its bowel-disease regimen requires baseline testing, monitoring through at least 16 weeks and periodic follow-up. Risankizumab's specified baseline and first-12-week induction monitoring applies to bowel disease. These distinctions do not imply that liver symptoms during psoriasis treatment can be ignored. Investigate suspected drug-induced injury and interrupt treatment until excluded; consider alternatives with cirrhosis, and with acute liver disease for guselkumab.
Treat biosimilars as regulated biologics
An FDA approved biosimilar has no clinically meaningful differences in safety, purity, and potency from its reference product within approved conditions. Product identity, interchangeability status, device, payer rules, and continuity still require careful implementation.
Quick check
Checking for saved practice…
Lesson
Stabilize Pustular and Erythrodermic Disease
Generalized pustular and erythrodermic psoriasis can disrupt temperature, fluid, cardiovascular, metabolic, and infection defenses. Management begins with stabilization and phenotype confirmation, not an outpatient cream escalation.
- Generalized pustular psoriasis
- IL-36 receptor
- Spesolimab
- Erythroderma
- Withdrawal flare
- Supportive care
Fever, pain, diffuse pustules, erythroderma, fluid loss, and organ change demand escalation.
Temperature, circulation, fluids, electrolytes, infection, pain, and nutrition require active care.
Spesolimab: IV for flares; SC between flares. After IV, begin SC at four weeks without another loading dose.
Stabilize before narrowing the drug list
Assess temperature, hemodynamics, oxygenation, fluid and electrolyte status, renal and hepatic function, infection, pain, nutrition, and medication exposure. Obtain dermatology support urgently.
Identify triggers and mimics
Infection, pregnancy, hypocalcemia, medication changes, and abrupt withdrawal of systemic corticosteroids or other effective therapy can precipitate severe disease. Pustules require differentiation from infection and severe drug reactions.
Use spesolimab for GPP
Spesolimab is an IL-36 receptor antagonist labeled for generalized pustular psoriasis in adults and patients 12 years and older who weigh at least 40 kg. It treats flares intravenously and can be used subcutaneously when not experiencing a flare.
Use the current dosing boundary
A flare is treated with 900 mg intravenously over 90 minutes, with one additional 900 mg dose one week later if symptoms persist. For a new subcutaneous start between flares, use 600 mg, followed by 300 mg at week four and every four weeks. After intravenous flare treatment, start or resume 300 mg subcutaneously four weeks later, without a loading dose.
Keep route and device instructions distinct
Intravenous vials require dilution and administration by a healthcare professional. Prefilled syringes are for subcutaneous use. A 600 mg loading dose using 150 mg syringes requires professional administration; with 300 mg syringes, a trained patient or caregiver may administer it when judged appropriate. Adolescents need adult supervision. Do not substitute a subcutaneous dose for acute intravenous flare treatment.
Respond to spesolimab safety signals
Avoid live vaccines during therapy and for at least 16 weeks afterward. Clinically important active infection requires withholding treatment until resolved or adequately treated. Serious allergy, including anaphylaxis or DRESS, requires immediate discontinuation and treatment; previous severe or life-threatening hypersensitivity is a contraindication.
Plan beyond one infusion
Evaluate TB and vaccination status, infection and hypersensitivity. The label reports Guillain-Barre syndrome during development in studies of unapproved indications; this does not establish its incidence or causality in GPP treatment. New progressive weakness or sensory symptoms need prompt evaluation. Other specialist options can include cyclosporine, infliximab, acitretin, methotrexate, or other pathway therapy based on phenotype, severity, prior response, and patient constraints.
Quick check
Checking for saved practice…
Lesson
Turn Response Into Durable Control
A treatment is successful only when disease burden falls, function returns, harm remains controlled, and the plan stays usable. Longitudinal care links targets, adherence, screening, vaccination, life stages, and switching decisions.
- Treatment target
- Vaccination
- Monitoring
- Pregnancy
- Adherence
- Switching
Skin activity, special sites, symptoms, joints, function, and quality of life define response.
Vaccines, infection, organs, mood, reproduction, and laboratory plans follow the exact treatment.
Efficacy, toxicity, access, preference, burden, and life changes justify deliberate transitions.
Set a measurable target
Document BSA or global assessment, special sites, symptoms, quality of life, joints, and photographs when helpful. Reassess on a timeline that fits the treatment and use shared goals such as clear or almost clear skin, minimal burden, and restored function.
Separate nonresponse from nonuse
Before switching, verify diagnosis, quantity, application, injection technique, schedule, access, storage, expectations, and whether the patient can follow the regimen. Secondary loss of response differs from never receiving adequate exposure.
Prevent avoidable immune risk
Complete age appropriate vaccines before immune modifying therapy when feasible. Avoid live vaccines with many systemic agents. Screen and monitor TB, hepatitis, infection, blood counts, liver, kidney, lipids, blood pressure, mood, or malignancy risk according to the exact treatment.
Plan reproductive care without legacy letters
Review pregnancy intention before teratogenic or immune modifying therapy. Methotrexate and acitretin have major reproductive restrictions. Narrowband UVB and selected biologics may be considered in coordinated specialist care, but decisions require current product and patient specific evidence.
Switch with a reason
Change treatment for inadequate efficacy, loss of response, toxicity, comorbidity, pregnancy planning, preference, access, or burden. Record the reason, washout or overlap plan, infection status, and the next measurement point.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 49 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- FDA Biosimilars: Overview for Health Care Professionals
- AAD Coal Tar Treatment Guidance
- AAD Nonprescription Psoriasis Care
- AAD Systemic Nonbiologic Psoriasis Supplementary Tables (2022)
- AAD Topical Corticosteroid Treatment Guidance
- AAD Pustular Psoriasis Treatment
- NPF Pustular Psoriasis Overview (2026)
- DailyMed ENBREL Label
- DailyMed CIMZIA Label
- DailyMed REMICADE Label
- DailyMed COSENTYX Label
- DailyMed TALTZ Label
- DailyMed SKYRIZI Label
- DailyMed TREMFYA Label
- DailyMed ILUMYA Label
- DailyMed STELARA Label
- DailyMed HUMIRA Label
- EULAR Reproductive Health Recommendations: 2024 Update (2025)
- ACR Reproductive Health Guideline (2020)
- AAD Psoriasis Phototherapy Supplemental Tables
- BAD/BPG Narrowband UVB Guideline (2022)
- AAD Psoriasis Clinical Guideline
- National Psoriasis Foundation Clinical Recommendations
- DailyMed SOTYKTU Label
- DailyMed ZORYVE Foam Label
- DailyMed ZORYVE Cream Label
- DailyMed VTAMA Label
- DailyMed BIMZELX Label
- DailyMed SPEVIGO Label
- DailyMed SILIQ Label
- DailyMed OTEZLA Label
- DailyMed Methotrexate Tablets Label
- DailyMed NEORAL Label
- DailyMed Oral Methoxsalen Label
- DailyMed DUOBRII Lotion Label
- DailyMed ENSTILAR Foam Label
- DailyMed TAZORAC Cream Label
- DailyMed Calcipotriene Cream Label
- DailyMed Acitretin Label